Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Bevacizumab Improves Survival in Cervical Cancer

Abstract: N Engl J Med. 2014;370(8):734-743.  Results of the Gynecologic Oncology Group (GOG) Trial 240 showed that the addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or … Continue reading

April 1, 2014

Glutathione for Prevention of Paclitaxel/Carboplatin-Induced Peripheral Neuropathy

Despite evidence supporting the potential benefit of glutathione in the prevention of chemotherapy-induced peripheral neuropathy (CIPN), results of this trial of 185 patients showed no benefit in preventing CIPN as … Continue reading

April 1, 2014

MITO-7 Focuses on Quality of Life: Weekly Carboplatin and Paclitaxel vs the Every 3-Week Standard

“Our primary study hypothesis was that the experimental weekly schedule could produce an improvement in health-related quality of life, compared with the standard schedule.” http://www.practiceupdate.com/expertopinion/833  Following the successful completion of … Continue reading

March 17, 2014

Carboplatin plus Paclitaxel Once a Week Versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multi-Centre, Open-Label, Phase 3 Trial

”A weekly regimen of carboplatin and paclitaxel might be a reasonable option for first-line treatment of women with advanced ovarian cancer.” http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970049- X/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, … Continue reading

March 17, 2014

TRINOVA-1 Signals New Direction in Ovarian Cancer

“Adding the investigational peptibody trebananib to weekly paclitaxel prolongs the time to disease progression or death in women with recurrent, advanced ovarian cancer, the phase III TRINOVA-1 trial has shown.” IMNG Medical … Continue reading

November 19, 2013

TRINOVA-1 Signals New Direction in Ovarian Cancer

“Adding the investigational peptibody trebananib to weekly paclitaxel prolongs the time to disease progression or death in women with recurrent, advanced ovarian cancer, the phase III TRINOVA-1 trial has shown.” IMNG Medical … Continue reading

November 19, 2013

Refining the Survival Benefit of Antiangiogenic Therapy in Advanced Ovarian Cancer

PRIME Oncology, October 2013 issue  Three reports at ECC presented data defining the survival benefit of antiangiogenic agents in subgroups of patients with advanced ovarian cancer. Two studies (ICON7 and … Continue reading

November 4, 2013

The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

“Recent studies suggest that carboplatin with pegylated liposomal doxorubicin (C+PLD) is as efficacious as carboplatin with paclitaxel (C+P) and possibly is more tolerable for ovarian cancer therapy.”  Jean-Marie Gibson, Saeed … Continue reading

October 16, 2013

Controversy in Treatment of Advanced Ovarian Cancer

“Although questions still remain over dosing and timing of first-line treatment for patients with advanced ovarian cancer, the JGOG study provides important data that will help guide patient care in … Continue reading

September 3, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada